Back to mobile site

Pfizer (PFE) Reiterated at Outperform by BMO Capital Following Earnings Report

February 8, 2022 7:47 AM EST Send to a Friend
BMO Capital analyst Evan David Seigerman reiterated an Outperform rating and $76.00 price target on Pfizer (NYSE: PFE), following the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login